NCT01209234

Brief Summary

This randomized controlled trial will compare strategies to reduce the risk of methicillin-resistant Staphylococcus aureus (MRSA) infection and re-hospitalization in MRSA carriers. This trial will provide critical answers about the role of decolonization versus standard-of-care education in preventing MRSA infections in the large group of high risk MRSA-positive patients being discharged from hospitals. Findings could potentially impact best practice for the 1.8 million MRSA carriers who are discharged from US hospitals each year.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,140

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2011

Longer than P75 for not_applicable

Geographic Reach
1 country

24 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 23, 2010

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 27, 2010

Completed
3 months until next milestone

Study Start

First participant enrolled

January 1, 2011

Completed
8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2019

Completed
1.7 years until next milestone

Results Posted

Study results publicly available

September 17, 2020

Completed
Last Updated

November 21, 2025

Status Verified

November 1, 2025

Enrollment Period

8 years

First QC Date

September 23, 2010

Results QC Date

August 12, 2019

Last Update Submit

November 5, 2025

Conditions

Keywords

Methicillin-resistant Staphylococcus aureusMRSA

Outcome Measures

Primary Outcomes (1)

  • Time to MRSA Infection

    Time in days to MRSA inpatient or outpatient infection (analyzed with the use of unadjusted Cox proportional-hazard models to identify time to infection; the results we are reporting are number of participants who had an infection event at one year post discharge)

    1 year

Secondary Outcomes (1)

  • Time to All-cause Infection (Steering Committee Modified Oct 2011)

    1 year

Other Outcomes (4)

  • Number of MRSA Infections

    1 year

  • Rehospitalization Due to MRSA Infection

    1 year

  • Cost and Cost Savings Associated With Post-discharge MRSA Decolonization

    1 year

  • +1 more other outcomes

Study Arms (2)

MRSA Decolonization

ACTIVE COMPARATOR

Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.

Drug: MRSA Decolonization

Education Arm

ACTIVE COMPARATOR

Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home. In addition, educational material on hygiene practices to prevent MRSA infection will be provided.

Behavioral: Standard-of-Care Education

Interventions

Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home.

Education Arm

Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.

MRSA Decolonization

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \) At least 18 years old
  • \) Have had a positive culture (a type of test) for MRSA during recent hospital admission or within the 30 days prior to admission or following discharge
  • \) Able to give consent or have a primary caregiver provide consent
  • \) Able to bathe or shower or have this consistently performed by a willing caregiver

You may not qualify if:

  • \) Known allergies to chlorhexidine or mupirocin

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (24)

Covington Care Center

Aliso Viejo, California, 92656, United States

Location

West Anaheim Extended Care

Anaheim, California, 92804, United States

Location

Downey Regional Medical Center

Downey, California, 90241, United States

Location

Fountain Valley Regional Hospital & Medical Center

Fountain Valley, California, 92708, United States

Location

Orange Coast Memorial Medical Center

Fountain Valley, California, 92708, United States

Location

St. Jude Medical Center

Fullerton, California, 92835, United States

Location

Chapman Care Center

Garden Grove, California, 92840, United States

Location

Pacific Haven HealthCare Center

Garden Grove, California, 92843, United States

Location

Regents Point at Windcrest

Irvine, California, 92612, United States

Location

Saddleback Memorial Medical Center - Laguna Hills

Laguna Hills, California, 92653, United States

Location

Long Beach Memorial Medical Center

Long Beach, California, 90806, United States

Location

St. Mary Medical Center

Long Beach, California, 90813, United States

Location

Mission Hospital

Mission Viejo, California, 92691, United States

Location

Hoag Memorial Hospital Presbyterian

Newport Beach, California, 92658, United States

Location

Villa Elena Health Care Center

Norwalk, California, 90650, United States

Location

UC Irvine Medical Center

Orange, California, 92868, United States

Location

Saddleback Memorial Medical Center - San Clemente

San Clemente, California, 92673, United States

Location

Little Company of Mary - San Pedro

San Pedro, California, 90732, United States

Location

Country Villa Plaza

Santa Ana, California, 92707, United States

Location

Royale Healthcare

Santa Ana, California, 92707, United States

Location

Torrance Memorial Medical Center

Torrance, California, 90505, United States

Location

Providence Little Company of Mary Medical Center

Torrance, California, 90732, United States

Location

Harbor-UCLA Medical Center

Torrence, California, 90502, United States

Location

Ventura County Medical Center

Ventura, California, 93003, United States

Location

Related Publications (5)

  • Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis. 2007 Dec;13(12):1840-6. doi: 10.3201/eid1312.070629.

    PMID: 18258033BACKGROUND
  • Huang SS, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis. 2003 Feb 1;36(3):281-5. doi: 10.1086/345955. Epub 2003 Jan 17.

    PMID: 12539068BACKGROUND
  • Huang SS, Hinrichsen VH, Stulgis L, Miroshnik I, Datta R, Watson K, Platt R. Methicillin-resistant Staphylococcus aureus Infection in the Year Following Detection of Carriage (oral presentation). Society of Healthcare Epidemiology of America Annual Meeting (Chicago, IL), March 18-21, 2006.

    BACKGROUND
  • Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK; Active Bacterial Core surveillance (ABCs) MRSA Investigators. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007 Oct 17;298(15):1763-71. doi: 10.1001/jama.298.15.1763.

    PMID: 17940231BACKGROUND
  • Huang SS, Singh R, McKinnell JA, Park S, Gombosev A, Eells SJ, Gillen DL, Kim D, Rashid S, Macias-Gil R, Bolaris MA, Tjoa T, Cao C, Hong SS, Lequieu J, Cui E, Chang J, He J, Evans K, Peterson E, Simpson G, Robinson P, Choi C, Bailey CC Jr, Leo JD, Amin A, Goldmann D, Jernigan JA, Platt R, Septimus E, Weinstein RA, Hayden MK, Miller LG; Project CLEAR Trial. Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers. N Engl J Med. 2019 Feb 14;380(7):638-650. doi: 10.1056/NEJMoa1716771.

Results Point of Contact

Title
Susan Huang, Principal Investigator & Medical Director of Epidemiology and Infection Prevention
Organization
University of California, Irvine

Study Officials

  • Susan S Huang, MD, MPH

    University of California, Irivne - School of Medicine

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of Epidemiology and Infection Prevention

Study Record Dates

First Submitted

September 23, 2010

First Posted

September 27, 2010

Study Start

January 1, 2011

Primary Completion

January 1, 2019

Study Completion

January 1, 2019

Last Updated

November 21, 2025

Results First Posted

September 17, 2020

Record last verified: 2025-11

Locations